Michael Lipp

Mike is a Co-Founder and Chief Technology Officer of Decoy Therapeutics. He has over two decades of experience in pharmaceutical development and drug delivery technologies ranging from the preclinical stage through commercial approval. Prior to joining Decoy, Mike was Senior Vice President of Pharmaceutical Development at Nocion Therapeutics. Prior to Nocion, Mike was Head of Pharmaceutical Development at Civitas Therapeutics through its acquisition by Acorda Therapeutics. Mike was Site Head of the Acorda Waltham R&D Facility and led the efforts related to the Chemistry, Manufacturing and Control (CMC) activities associated with InbrijaTM which was approved by the FDA in 2018 for the treatment of OFF episodes in Parkinson’s Disease. Prior to Civitas, Mike was Vice President of Pharmaceutical Development and Intellectual Property at Pulmatrix where he was a co-inventor of the iSPERSETM pulmonary dry powder technology. Prior to that, he was Director of Formulation Development at Alkermes. Mike began his career as a Post-Doctoral Fellow working with Advanced Inhalation Research (AIR®), where he became a Staff Scientist focusing on pulmonary product development prior to its acquisition by Alkermes.